SEMAX 50mg from Adaptog Peptides is a synthetic heptapeptide derived from a fragment of ACTH (4-10), widely used in cognitive, neuroprotective, and neurotrophic research. Investigators select SEMAX for its documented influence on BDNF expression and neurochemical signalling. Adaptog supplies SEMAX 50mg as a high-purity laboratory reagent suited to studies that require dependable performance across extended protocols.
SEMAX features prominently in nootropic and neuroprotective research because of its modulatory effects on growth-factor expression and central neurotransmitter systems. Adaptog Peptides supplies SEMAX 50mg in a vial size that supports longer experimental timelines and larger sample volumes, giving researchers flexibility across study designs.
Researchers often buy SEMAX 50mg from Adaptog Peptides for studies such as:
Examining BDNF and NGF expression in controlled neural models
Investigating cognitive-related signalling pathways
Studying neuroprotective markers under ischaemic or oxidative stress conditions
Mapping interactions with serotonergic and dopaminergic systems
Because SEMAX intersects neurotrophic biology, cognition research, and neurochemistry, it supports a wide spectrum of investigative work. Adaptog Peptides delivers SEMAX 50mg as a research-grade compound prepared exclusively for qualified laboratory environments. It does not serve any clinical, diagnostic, or therapeutic purpose.
For research use only. Not for human consumption.
SEMAX features prominently in nootropic and neuroprotective research because of its modulatory effects on growth-factor expression and central neurotransmitter systems. Adaptog Peptides supplies SEMAX 50mg in a vial size that supports longer experimental timelines and larger sample volumes, giving researchers flexibility across study designs.
Researchers often buy SEMAX 50mg from Adaptog Peptides for studies such as:
Examining BDNF and NGF expression in controlled neural models
Investigating cognitive-related signalling pathways
Studying neuroprotective markers under ischaemic or oxidative stress conditions
Mapping interactions with serotonergic and dopaminergic systems
Because SEMAX intersects neurotrophic biology, cognition research, and neurochemistry, it supports a wide spectrum of investigative work. Adaptog Peptides delivers SEMAX 50mg as a research-grade compound prepared exclusively for qualified laboratory environments. It does not serve any clinical, diagnostic, or therapeutic purpose.
For research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Not a researcher? Exit
